Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ETER901: Benmelstobart + Anlotinib vs Nab-Paclitaxel in First-Line Advanced TNBC
NCT04405505Phase 3Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jun 2020
- Primary completion
- Jul 2022
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of benmelstobart in triple-negative breast cancer (TNBC), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Status: unknown.
02
Drugs
benmelstobart
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT04405505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04405505.